+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PCSK9 Antagonists Market - Global Forecast 2025-2030- Product Image
PCSK9 Antagonists Market - Global Forecast 2025-2030- Product Image
Sale

PCSK9 Antagonists Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6124158
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The market for PCSK9 antagonists is experiencing strong, strategic growth, fueled by advances in biologic therapies and evolving payer frameworks. Senior leaders face an environment requiring agile adaptation to regulatory shifts, emerging molecular platforms, and complex supply chains. The evolving ecosystem delivers expanded therapeutic options for at-risk populations seeking long-term LDL-cholesterol reduction.

Market Snapshot: PCSK9 Antagonists

The PCSK9 antagonist market is on an upward trajectory, with solid year-over-year expansion in line with rising cardiovascular disease prevalence and healthcare system investments. New approvals of monoclonal antibodies and RNA interference therapies support diversified adoption across a spectrum of healthcare settings, including hospitals, specialty clinics, and homecare. Widespread integration of digital health tools and the expansion of value-based contracting models continue to refine real-world utilization and therapy outcomes for high-risk patient segments.

Scope & Segmentation

This report delivers comprehensive segmentation to help stakeholders understand the complex PCSK9 antagonist landscape, including current and next-generation delivery strategies.

  • Molecule: Alirocumab, Evolocumab, and Inclisiran, each offering differentiated pathways—monoclonal antibodies or RNA interference—to address LDL-C reduction goals
  • Application: Broad use in atherosclerotic cardiovascular disease, with additional focus on acute coronary syndrome management, long-term stabilization of angina, stroke prevention, as well as treating heterozygous and homozygous familial hypercholesterolemia
  • Dosage Form: Accessible delivery via prefilled pens for self-injection, prefilled syringes or vials for clinical use, enabling patient-centric or provider-administered therapy
  • End User: Versatile adoption across homecare, hospital settings, and specialty clinics—ensuring tailored care, adherence support, and acute intervention
  • Distribution Channel: Comprehensive reach via hospital, online, and retail pharmacies—optimizing patient access and treatment continuity
  • Regions: In-depth analysis of Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)

Key Takeaways for Senior Decision-Makers

  • PCSK9 antagonists mark a paradigm shift in targeted cardiovascular care, as biologic and RNA platforms advance both efficacy and dosing convenience.
  • Monoclonal antibodies and next-generation RNA interference agents allow flexible administration, aligning with patient preferences and improving adherence across settings.
  • Evolving payer strategies leverage value-based and outcomes-linked agreements, fostering cost-effectiveness and expanding high-impact therapy access.
  • Digital health platforms and remote monitoring support data-driven, personalized care, strengthening communication and outcome tracking.
  • Manufacturers, facing increased input costs due to new US tariffs, are shifting supply chain strategies, balancing domestic sourcing with operational efficiency.
  • Regional regulatory harmonization and tailored pricing approaches unlock localized opportunities, particularly in growth-focused Asia-Pacific and cost-conscious EMEA markets.

Tariff Impact on PCSK9 Supply Chains

Recent US tariff measures have reshaped supply chains, prompting manufacturers to diversify sourcing, invest in domestic capability, and realign costs. These actions require cross-functional capital planning and careful reassessment of pricing and reimbursement frameworks. Organizations responding with proactive strategies are more likely to maintain resilience and secure uninterrupted supply.

Methodology & Data Sources

This report synthesizes insights from primary interviews with key opinion leaders, supported by secondary reviews of peer-reviewed research, regulatory filings, and industry disclosures. Quantitative modeling maps patient demographics, treatment adoption, and supply chain dynamics. Rigorous data triangulation and multidisciplinary review ensure analytical integrity and up-to-date market perspectives.

Why This Report Matters

  • Provides actionable intelligence for product positioning, risk management, and investment decision-making in the PCSK9 antagonist sector.
  • Helps leaders anticipate regulatory changes and optimize payer reimbursement strategies in core and emerging geographies.
  • Enables data-driven market entry and expansion planning, supported by robust methodology and real-world evidence analysis.

Conclusion

PCSK9 antagonists continue to transform cholesterol management through scientific innovation, strategic partnerships, and adaptive commercial strategies. Forward-looking organizations leveraging these market dynamics can enhance patient access and sustain growth within the evolving therapeutic landscape.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing real-world adoption of inclisiran therapy driven by favorable dosing schedule and payer coverage
5.2. Strategic partnerships between biotechs and CDMOs to accelerate subcutaneous PCSK9 antibody production and diversification across geographies
5.3. Advanced pipeline strategies focusing on RNA interference and gene editing approaches targeting PCSK9 for durable lipid lowering
5.4. Competitive pricing pressures emerging from biosimilars and novel oral PCSK9 inhibitors reshaping market access dynamics
5.5. Growing emphasis on cardiovascular outcomes data integration to support PCSK9 therapy reimbursement across emerging markets
5.6. Expansion of telehealth-led lipid management programs incorporating PCSK9 antagonists to enhance patient engagement and adherence
5.7. Leveraging AI-driven predictive analytics to identify high-risk patients for PCSK9 antagonist therapy in population health management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PCSK9 Antagonists Market, by Molecule
8.1. Introduction
8.2. Alirocumab
8.3. Evolocumab
8.4. Inclisiran
9. PCSK9 Antagonists Market, by Application
9.1. Introduction
9.2. Atherosclerotic Cardiovascular Disease
9.2.1. Acute Coronary Syndrome
9.2.2. Stable Angina Pectoris
9.2.3. Stroke Prevention
9.3. Heterozygous Familial Hypercholesterolemia
9.4. Homozygous Familial Hypercholesterolemia
10. PCSK9 Antagonists Market, by Dosage Form
10.1. Introduction
10.2. Prefilled Pen
10.3. Prefilled Syringe
10.4. Vial
11. PCSK9 Antagonists Market, by End User
11.1. Introduction
11.2. Homecare Settings
11.3. Hospitals
11.4. Specialty Clinics
12. PCSK9 Antagonists Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas PCSK9 Antagonists Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa PCSK9 Antagonists Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific PCSK9 Antagonists Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Amgen Inc.
16.3.2. Sanofi S.A.
16.3.3. Regeneron Pharmaceuticals, Inc.
16.3.4. Novartis AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PCSK9 ANTAGONISTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PCSK9 ANTAGONISTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PCSK9 ANTAGONISTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. PCSK9 ANTAGONISTS MARKET: RESEARCHAI
FIGURE 26. PCSK9 ANTAGONISTS MARKET: RESEARCHSTATISTICS
FIGURE 27. PCSK9 ANTAGONISTS MARKET: RESEARCHCONTACTS
FIGURE 28. PCSK9 ANTAGONISTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PCSK9 ANTAGONISTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY INCLISIRAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY INCLISIRAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY STABLE ANGINA PECTORIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY STABLE ANGINA PECTORIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PCSK9 ANTAGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES PCSK9 ANTAGONISTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 85. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 86. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 87. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 90. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 91. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 92. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 93. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. CANADA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 98. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 99. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 103. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 104. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 105. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. MEXICO PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 160. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 161. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 164. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 165. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 166. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 167. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. GERMANY PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 172. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 173. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 176. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 177. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 178. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 179. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. FRANCE PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 196. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 197. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 200. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 201. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 202. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 203. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. ITALY PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 208. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 209. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 212. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 213. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 214. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 215. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. SPAIN PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 256. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 257. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 260. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 261. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 262. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 263. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. DENMARK PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 280. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 281. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 282. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 283. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 284. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 285. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 286. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 287. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. QATAR PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 292. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 293. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 294. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 295. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 296. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 297. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 298. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 299. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. FINLAND PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 304. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. SWEDEN PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 316. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 323. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 325. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 326. NIGERIA PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 327. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 328. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 329. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 330. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 331. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
TABLE 332. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, 2025-2030 (USD MILLION)
TABLE 333. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 334. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 335. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 336. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 337. EGYPT PCSK9 ANTAGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this PCSK9 Antagonists market report include:
  • Amgen Inc.
  • Sanofi S.A.
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG

Related Reports

PCSK9 Targeted Drugs Market - Global Forecast 2025-2030 - Product Image

PCSK9 Targeted Drugs Market - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Cholesterol Lowering Drug Market - Global Forecast 2025-2030 - Product Image

Cholesterol Lowering Drug Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2025 - Product Image

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Hyperlipidemia Drugs - Global Strategic Business Report - Product Image

Hyperlipidemia Drugs - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
PCSK9 Inhibitor Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

PCSK9 Inhibitor Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.